Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.10), MarketWatch Earnings reports.
SGTX opened at $0.75 on Friday. The business’s 50-day moving average price is $1.30 and its 200-day moving average price is $2.29. Sigilon Therapeutics has a 12 month low of $0.75 and a 12 month high of $14.15.
Separately, Zacks Investment Research raised Sigilon Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Thursday, March 17th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $6.20.
About Sigilon Therapeutics (Get Rating)
Sigilon Therapeutics, Inc, a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes.
- Get a free copy of the StockNews.com research report on Sigilon Therapeutics (SGTX)
- The Three Most Upgraded Stocks You Can Buy Now
- MarketBeat: Week in Review 5/9 – 5/13
- Is Electronic Arts (NASDAQ: EA) Suddenly A Safe Haven?
- Beyond Meat Stock Value is Improving
- The Travel Sector Is Getting Upgraded
Receive News & Ratings for Sigilon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sigilon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.